| Abstract | 第8-11页 |
| 摘要 | 第12-26页 |
| Chapter 1Review of natural bioactive compounds and application of novel drug deliverysystems | 第26-44页 |
| 1.1 Introduction | 第26-27页 |
| 1.2 Natural bioactive substances | 第27-28页 |
| 1.3 Review of perillaldehyde | 第28-34页 |
| 1.3.1 Source | 第28-29页 |
| 1.3.2 Physicochemical properties | 第29-30页 |
| 1.3.3 Methods of extraction | 第30-31页 |
| 1.3.4 Pharmacological activities | 第31-33页 |
| 1.3.5 Pharmaceutical applications and pharmacokinetics | 第33-34页 |
| 1.3.6 Limitations of PAH and future prospects | 第34页 |
| 1.4 Novel drug delivery systems | 第34-42页 |
| 1.4.1 Lipid-based drug delivery systems (LBDDS) | 第35-42页 |
| 1.5 Objectives and significance of study | 第42-44页 |
| Chapter 2 Perillaldehyde-loaded lipid nanoformulations: Preparations, optimization andcharacterization | 第44-78页 |
| 2.1 Introduction | 第44-47页 |
| 2.2 Instruments, materials and reagents | 第47-48页 |
| 2.2.1 Instruments | 第47-48页 |
| 2.2.2 Materials and reagents | 第48页 |
| 2.3 Experimental design and methodology | 第48-57页 |
| 2.3.1 Analytical methods for in vitro quantification of PAH | 第48-49页 |
| 2.3.2 Preparation and optimization of PAH-loaded SNEDDS (PAH-SNEDS) | 第49-53页 |
| 2.3.3 Preparation, optimization and characterization of PAH loaded liposomalnanoformulation (PAH-LNF) | 第53-54页 |
| 2.3.4 Preparation of PAH-SNEDS pellets via extrusion spheronization | 第54-56页 |
| 2.3.5 Statistical analysis | 第56-57页 |
| 2.4 Results and discussion | 第57-76页 |
| 2.4.1 In vitro quantification of PAH | 第57-59页 |
| 2.4.2 Preparation and optimization of PAH-SNEDS | 第59-65页 |
| 2.4.3 Preparation and optimization of PAH-LNF | 第65-69页 |
| 2.4.4 Morphology, droplet size and polydispersity index | 第69-70页 |
| 2.4.5 In vitro release profile of PAH-SNEDS and PAH-LNF | 第70-72页 |
| 2.4.6 Stability of PAH- SNEDS and PAH-LNF | 第72-73页 |
| 2.4.7 Preparation of PAH-SNEDS pellets | 第73-75页 |
| 2.4.8 In vitro release profile of PAH-SNEDS pellets | 第75-76页 |
| 2.4.9 Release mechanism | 第76页 |
| 2.5 Summary | 第76-78页 |
| 2.5.1 Graphical Summary | 第77-78页 |
| Chapter 3 Oral bioavailability and anti-hyperlipidemic potential of perillaldehyde-loadedself nanoemulsifying delivery system against high-fat diet induced hyperlipidemia | 第78-93页 |
| 3.1 Introduction | 第78-79页 |
| 3.2 Instruments, materials and reagents | 第79-80页 |
| 3.2.1 Instruments | 第79-80页 |
| 3.2.2 Materials and reagents | 第80页 |
| 3.2.3 Animals | 第80页 |
| 3.3 Experimental design and methodologies | 第80-83页 |
| 3.3.1 Bioavailability studies of PAH-SNEDS in rats | 第80-82页 |
| 3.3.2 High-fat diet induced hyperlipidemic mice model and treatment | 第82-83页 |
| 3.3.3 Statistical analysis | 第83页 |
| 3.4 Results and discussions | 第83-91页 |
| 3.4.1 Quantification of PAH in vivo | 第83-86页 |
| 3.4.2 In vivo pharmacokinetics | 第86-88页 |
| 3.4.3 Effect of PAH-SNEDS on body weight, liver and heart | 第88-89页 |
| 3.4.4 Effect of PAH-SNEDS on serum lipid profile | 第89-90页 |
| 3.4.5 Histopathological observations | 第90-91页 |
| 3.5 Summary | 第91-93页 |
| 3.5.1 Graphical Summary | 第92-93页 |
| Chapter 4 Tissue distribution and anti-hyperlipidemic activity of perillaldehyde liposomalnanoformulation against Poloxamer-407 induced hyperlipidemia | 第93-108页 |
| 4.1 Introduction | 第93-94页 |
| 4.2 Instruments, materials and reagents | 第94-95页 |
| 4.2.1 Instruments | 第94页 |
| 4.2.2 Materials and reagents | 第94-95页 |
| 4.2.3. Animal experiments | 第95页 |
| 4.3 Experimental design and methodologies | 第95-98页 |
| 4.3.1 Bioavailability studies of PAH-LNF in rats | 第95-96页 |
| 4.3.2 Tissue distribution of PAH-LNF in mice | 第96-97页 |
| 4.3.3 Poloxamer-407 induced hyperlipidemia and treatment | 第97-98页 |
| 4.3.4. Statistical analysis | 第98页 |
| 4.4 Results and discussion | 第98-106页 |
| 4.4.1 In vivo pharmacokinetics | 第98-100页 |
| 4.4.2 Tissue distribution | 第100-103页 |
| 4.4.3 Effect of PAH-LNF on serum lipid profile levels in Poloxamer 407- inducedhyperlipidemic mice | 第103页 |
| 4.4.4 Effect of PAH-LNF on hepatic antioxidant levels in Poloxamer-407 inducedhyperlipidemic mice | 第103-105页 |
| 4.4.5 Effect of PAH-LNF on hepatic enzyme activity in Poloxamer-407 inducedhyperlipidemic mice | 第105-106页 |
| 4.5 Summary | 第106-108页 |
| 4.5.1 Graphical Summary | 第107-108页 |
| Chapter 5 In situ intestinal perfusion, anti-hyperglycaemic, antioxidant and anti-inflammatory investigations of PAH-SNEDS in alloxan-induced diabetes | 第108-127页 |
| 5.1 Introduction | 第108-110页 |
| 5.2. Instruments, materials and reagents | 第110-111页 |
| 5.2.1 Instruments | 第110-111页 |
| 5.2.2 Materials and reagents | 第111页 |
| 5.2.3. Animals | 第111页 |
| 5.3. Experimental design and methodologies | 第111-116页 |
| 5.3.1 Preparation of PAH-SNEDS | 第111-112页 |
| 5.3.2 In situ intestinal absorption of PAH in rats | 第112-114页 |
| 5.3.3 Anti-hyperglycaemic investigations of PAH | 第114-116页 |
| 5.3.4 Statistical analysis | 第116页 |
| 5.4 Results and discussion | 第116-125页 |
| 5.4.1 Intestinal adsorption and absorption study in rat | 第116-119页 |
| 5.4.2 Anti-hyperglycaemic activity of PAH-SNEDS | 第119-125页 |
| 5.5 Summary | 第125-127页 |
| 5.5.1 Graphical Summary | 第126-127页 |
| Chapter 6 General conclusions and future work | 第127-131页 |
| 6.1 General conclusions | 第127-130页 |
| 6.2 Innovations/Novelty | 第130页 |
| 6.3 Considerations for Future work | 第130-131页 |
| References | 第131-147页 |
| Acknowledgement | 第147-148页 |
| Publications | 第148-150页 |
